rheumatoid arthritis

Peresolimab, a humanized IgG1 monoclonal antibody treatment for rheumatoid arthritis, shows promising results in phase 2a trial

by

According to a phase 2a study published in New England Journal of Medicine, peresolimab has shown effectiveness in rheumatoid arthritis (RA) patients. Peresolimab is a humanized IgG1 monoclonal antibody that accelerates the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. PD-1 acts as a negative regulator and immunological checkpoint inhibitor, inhibiting T-cell responses. The … Read more

Patient input in a digital health application enhances the patient-reported outcomes in rheumatoid arthritis

by

According to a study published in JAMA Network Open, rheumatoid arthritis (RA) patients who use a digital health application to evaluate their patient-reported outcomes are more likely to report controlled disease activity. Dr. Li and colleagues conducted the multicenter, open-label, randomized study to examine the effects of employing a digital application to monitor patient-reported outcomes … Read more

ASCORE study reports improved abatacept retention and clinical response rates in patients who received early subcutaneous abatacept

by

Recently, the findings of the international ASCORE study published in Clinical Rheumatology found that the 2-year retention rate for subcutaneous (SC) abatacept was 47%, accompanied by favorable clinical outcomes and good tolerability. Patients who received abatacept as an earlier-line biologic drug treatment and those with seropositive rheumatoid arthritis (RA) experienced higher rates of abatacept retention … Read more

Study reports comparable treatment effects of biosimilars and reference biologics in rheumatoid arthritis

by

Adalimumab, infliximab, and etanercept biosimilars were found to have clinically equal treatment effects compared to their reference biologics for the treatment of rheumatoid arthritis (RA), according to a review and meta-analysis published in JAMA Network Open. The study included a total of 10,642 RA patients who were using biosimilars of the drugs adalimumab, etanercept, and … Read more

Olokizumab, a new drug for managing rheumatoid arthritis

by

Despite the recent therapeutic advances, nearly 25% of patients are refractory to the treatment regimens. The findings of an international multi-centre study led by MedUni Vienna, published in the New England Journal of Medicine, have reported olokizumab as a newer treatment option with promising results for the management of RA. Olokizumab, the humanized monoclonal antibody, … Read more